(NASDAQ: CCCC) C4 Therapeutics's forecast annual revenue growth rate of -20.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
C4 Therapeutics's revenue in 2026 is $34,861,000.On average, 9 Wall Street analysts forecast CCCC's revenue for 2026 to be $2,134,389,653, with the lowest CCCC revenue forecast at $650,135,265, and the highest CCCC revenue forecast at $3,448,038,818. On average, 9 Wall Street analysts forecast CCCC's revenue for 2027 to be $2,339,049,581, with the lowest CCCC revenue forecast at $650,135,265, and the highest CCCC revenue forecast at $3,448,038,818.
In 2028, CCCC is forecast to generate $1,824,248,596 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,448,038,818.